Adaptimmune Therapeutics (ADAP) Earnings Date, Estimates & Call Transcripts → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free adap Stock Alerts $1.24 +0.09 (+7.83%) (As of 05/15/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryLatest Earnings DateMar. 6ConfirmedActual EPS (Mar. 6) -$0.24 Missed By -$0.12 Consensus EPS (Mar. 6) -$0.12 Get Adaptimmune Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for ADAP and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueADAP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ADAP Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Crypto 101 MediaA ‘DeFi Summer’ Projected!Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x!Just click here to learn how you can access this coin right now. Adaptimmune Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.12)($0.12)($0.12)Q2 20241($0.13)($0.13)($0.13)Q3 20241($0.12)($0.12)($0.12)Q4 20241($0.11)($0.11)($0.11)FY 20244($0.48)($0.48)($0.48)ADAP Earnings Date and InformationAdaptimmune Therapeutics last released its quarterly earnings data on March 6th, 2024. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.12. The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $4.80 million. Adaptimmune Therapeutics has generated ($0.55) earnings per share over the last year (($0.55) diluted earnings per share). Earnings for Adaptimmune Therapeutics are expected to grow in the coming year, from ($0.49) to ($0.48) per share. Read More Adaptimmune Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript3/6/2024Q4 2023($0.12)($0.24)($0.12)($0.24)$4.80 million$0.23 million11/8/2023Q3 2023($0.20)($0.20)-($0.20)$5.00 million$7.32 million8/9/2023Q2 2023($0.17)($0.21)($0.04)($0.30)$5.00 million$5.13 million5/12/2023Q1 2023($0.19)$0.01+$0.20$0.01$7.70 million$47.60 million3/6/2023Q4 2022($0.25)($0.18)+$0.07($0.18)$7.50 million$11.03 million11/8/2022Q3 2022($0.28)($0.24)+$0.04($0.24)$4.40 million$7.01 million Get the Latest News and Ratings for ADAP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/4/2022Q2 2022($0.28)($0.28)-($0.28)$12.25 million$5.54 million5/9/2022Q1 2022($0.26)($0.32)($0.06)($0.32)$4.00 million$3.58 million 3/14/2022Q4 2021($0.22)($0.25)($0.03)($0.25)$80.25 million$1.42 million 11/4/2021Q3 2021($0.26)($0.30)($0.04)($0.27)$1.20 million$1.20 million 8/8/2021Q2 2021($0.25)($0.24)+$0.01($0.24)$0.60 million$3.10 million Adaptimmune Therapeutics Earnings - Frequently Asked Questions When did Adaptimmune Therapeutics announce their last quarterly earnings? Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earning data on Wednesday, March 6, 2024. Learn more on ADAP's earnings history. Did Adaptimmune Therapeutics beat their earnings estimates last quarter? In the previous quarter, Adaptimmune Therapeutics (NASDAQ:ADAP) missed the analysts' consensus estimate of ($0.12) by $0.12 with a reported earnings per share (EPS) of ($0.24). Learn more on analysts' earnings estimate vs. ADAP's actual earnings. How much revenue does Adaptimmune Therapeutics generate each year? Adaptimmune Therapeutics (NASDAQ:ADAP) has a recorded annual revenue of $60.28 million. How much profit does Adaptimmune Therapeutics generate each year? Adaptimmune Therapeutics (NASDAQ:ADAP) has a recorded net income of -$113.87 million. ADAP has generated -$0.55 earnings per share over the last four quarters. What is Adaptimmune Therapeutics's EPS forecast for next year? Adaptimmune Therapeutics's earnings are expected to grow from ($0.49) per share to ($0.48) per share in the next year. More Earnings Resources from MarketBeat Related Companies: STRO Earnings CADL Earnings PSTX Earnings GLUE Earnings FENC Earnings CHRS Earnings IVVD Earnings AGEN Earnings CMPX Earnings AVXL Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Home Depot: Earnings Mixed, Wait to Buy the DipTraders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong Earnings This page (NASDAQ:ADAP) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTop 5 AI Stocks to Buy for 2024Market Moving TrendsThis unknown company solves the biggest issue with AIManward PressTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
